Oct 1, 2026 09:00AM
Aug 12, 2026 07:00AM
Aug 5, 2026 07:00AM
Jun 17, 2026 04:01PM
Jun 17, 2026 04:01PM
Jun 15, 2026 07:01AM
Jun 15, 2026 07:00AM Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia
May 11, 2026 09:53AM
May 11, 2026 07:00AM
Apr 27, 2026 05:15PM
Mar 31, 2026 07:38AM
Mar 30, 2026 04:05PM
Jan 12, 2026 07:01AM
Jan 12, 2026 07:00AM Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy
Dec 17, 2025 04:05PM
Nov 5, 2025 07:36AM
Oct 8, 2025 06:46AM
Oct 7, 2025 06:01AM
Oct 7, 2025 06:00AM
Aug 14, 2025 07:30AM
Jul 7, 2025 07:37AM Stifel Reiterates Buy Rating on Lexeo Therapeutics (LXEO)
Jul 7, 2025 07:01AM
Jul 7, 2025 07:00AM
Jun 5, 2025 12:44PM
May 12, 2025 07:00AM
Apr 8, 2025 06:46AM
Apr 7, 2025 06:22AM
Apr 7, 2025 06:00AM Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study
Mar 26, 2025 06:50AM
Mar 24, 2025 07:00AM
Nov 14, 2024 06:59AM
Nov 13, 2024 07:30AM
Oct 30, 2024 06:16AM
Oct 30, 2024 06:14AM
Oct 22, 2024 07:30AM Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference
Aug 16, 2024 05:30AM
Aug 12, 2024 07:00AM
Jul 15, 2024 07:39AM
Jul 15, 2024 06:02AM
Jul 15, 2024 06:00AM
May 9, 2024 07:00AM
Apr 22, 2024 07:30AM Lexeo Therapeutics (LXEO) Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Apr 22, 2024 07:30AM
Apr 16, 2024 07:30AM
Apr 16, 2024 07:30AM
Mar 11, 2024 07:42AM
Feb 5, 2024 07:00AM
Dec 18, 2023 07:04AM
Dec 18, 2023 07:00AM Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
Dec 11, 2023 07:00AM

334,273 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All